US neurologists prescribing oral MS drug Tecfidera in growing numbers
BioTrends Research Group finds that, despite being the third oral disease-modifying therapy (DMT) to launch in the U.S. multiple sclerosis (MS) market, 53 percent of surveyed U.S. neurologists have prescribed Biogen Idec's Tecfidera to at least one of their MS patients after only one month on the market. This rate for Tecfidera surpasses that for Novartis's Gilenya (19 percent), the first-to-market oral DMT, and Genzyme's Aubagio (16 percent), the second-to-market oral DMT, at the same stage of product launch.... Read More - http://www.ms-uk.org/index.cfm/BG12
US neurologists prescribing oral MS drug Tecfidera.....
US neurologists prescribing oral MS drug Tecfidera.....
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 4547 Views
-
Last post by NHE
-
- 0 Replies
- 1640 Views
-
Last post by NHE
-
- 0 Replies
- 1884 Views
-
Last post by NHE
-
- 0 Replies
- 8881 Views
-
Last post by NHE
-
- 8 Replies
- 7155 Views
-
Last post by Algis
-
- 0 Replies
- 2341 Views
-
Last post by NHE
-
- 1 Replies
- 1019 Views
-
Last post by Petr75
-
- 0 Replies
- 1297 Views
-
Last post by NHE
-
- 1 Replies
- 2700 Views
-
Last post by Tif